Приказ основних података о документу

dc.creatorAntić, J.
dc.creatorVasiljević, T.
dc.creatorStanojević, Stanislava
dc.creatorVujić, Vesna
dc.creatorKovačević-Jovanović, Vesna
dc.creatorĐergović, Danica
dc.creatorMiljević, C.
dc.creatorMarković, B.M.
dc.creatorRadulović, Jelena
dc.date.accessioned2021-02-18T10:19:09Z
dc.date.available2021-02-18T10:19:09Z
dc.date.issued1996
dc.identifier.issn0162-3109
dc.identifier.urihttp://intor.torlakinstitut.com/handle/123456789/65
dc.description.abstractIt is well established that K-opioid receptor agonists exert antiinflammatory and antihyperalgesic effects during nonspecific inflammation as well as suppressive effects on the development of humoral and cell-mediated immune responses to foreign antigens. The aim of this study was to investigate the ability of the K-opioid receptor agonist MR 2034 to modulate adjuvant arthritis in the rat. In the first series of experiments, treatments of Wistar rats were performed using several routes of drug administration: intraperitoneal (ip), intracaudal (ic), intracerebroventricular (icy) and intraplantar (ipl). MR 2034 significantly suppressed joint swelling after ip and ic treatment, slightly reduced inflammation after ipl treatment, and did not produce any effect after icy treatment. In the second series of experiments, the suppressive effect of ip injected MR 2034 was investigated using Wistar, Dark August (DA) and Lewis rats. In Wistar rats, MR 2034 significantly decreased the incidence of adjuvant arthritis, and suppressed mean joint score and aggregate joint score. Similarly, in DA rats treated with MR 2034, mean arthritic score was significantly suppressed, but other clinical parameters were not affected. In Lewis rats, however, ip treatment with MR 2034 failed to produce any suppressive effect on joint disease and even potentiated the initial development of arthritis. These data suggest that immunosuppressive and antiinflammatory action of MR 3034 markedly depend on the route of drug administration and strain susceptibility to opioids.en
dc.publisherElsevier, Amsterdam
dc.rightsrestrictedAccess
dc.sourceImmunopharmacology
dc.subjectadjuvant arthritisen
dc.subjectimmunosuppressionen
dc.subjectkappa-opioid agonisten
dc.subjectrat strainsen
dc.titleSuppression of adjuvant arthritis by kappa-opioid receptor agonist: Effect of route of administration and strain differencesen
dc.typearticle
dc.rights.licenseARR
dc.citation.epage112
dc.citation.issue2-3
dc.citation.other34(2-3): 105-112
dc.citation.spage105
dc.citation.volume34
dc.identifier.doi10.1016/0162-3109(96)00114-2
dc.identifier.pmid8886854
dc.identifier.scopus2-s2.0-0030245662
dc.identifier.wosA1996VG47300005
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу